Details for Patent: RE49444
✉ Email this page to a colleague
Which drugs does patent RE49444 protect, and when does it expire?
Patent RE49444 protects TYMLOS and is included in one NDA.
This patent has thirty-nine patent family members in twenty-five countries.
Drugs Protected by US Patent RE49444
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Radius | TYMLOS | abaloparatide | SOLUTION;SUBCUTANEOUS | 208743-001 | Apr 28, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE. | ⤷ Sign Up | ||||
| Radius | TYMLOS | abaloparatide | SOLUTION;SUBCUTANEOUS | 208743-001 | Apr 28, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT TO INCREASE BONE DENSITY IN MEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent RE49444
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2073789 | ⤷ Sign Up | 301235 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2073789 | ⤷ Sign Up | CA 2023 00019 | Denmark | ⤷ Sign Up |
| European Patent Office | 2073789 | ⤷ Sign Up | 2023C/523 | Belgium | ⤷ Sign Up |
| European Patent Office | 2073789 | ⤷ Sign Up | LUC00309 | Luxembourg | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
